ATE437876T1 - Hexahydropyridoisochinoline als dpp-iv- inhibitoren - Google Patents
Hexahydropyridoisochinoline als dpp-iv- inhibitorenInfo
- Publication number
- ATE437876T1 ATE437876T1 AT04739825T AT04739825T ATE437876T1 AT E437876 T1 ATE437876 T1 AT E437876T1 AT 04739825 T AT04739825 T AT 04739825T AT 04739825 T AT04739825 T AT 04739825T AT E437876 T1 ATE437876 T1 AT E437876T1
- Authority
- AT
- Austria
- Prior art keywords
- hexahydropyridoisochinolines
- dpp
- inhibitors
- Prior art date
Links
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03013405 | 2003-06-20 | ||
| PCT/EP2004/006336 WO2005000846A1 (en) | 2003-06-20 | 2004-06-11 | Hexahydropyridoisoqinolines as dpp-iv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437876T1 true ATE437876T1 (de) | 2009-08-15 |
Family
ID=33515112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04739825T ATE437876T1 (de) | 2003-06-20 | 2004-06-11 | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7718666B2 (de) |
| EP (1) | EP1638968B1 (de) |
| JP (1) | JP4445504B2 (de) |
| KR (1) | KR100744893B1 (de) |
| CN (1) | CN101090901B (de) |
| AR (1) | AR044796A1 (de) |
| AT (1) | ATE437876T1 (de) |
| AU (1) | AU2004251829B2 (de) |
| BR (1) | BRPI0411509A (de) |
| CA (1) | CA2528784C (de) |
| CO (1) | CO5640136A2 (de) |
| DE (1) | DE602004022294D1 (de) |
| ES (1) | ES2327740T3 (de) |
| IL (1) | IL172330A (de) |
| MX (1) | MXPA05013734A (de) |
| NO (1) | NO20055680L (de) |
| NZ (1) | NZ543863A (de) |
| RU (1) | RU2339636C2 (de) |
| TW (1) | TW200504063A (de) |
| WO (1) | WO2005000846A1 (de) |
| ZA (1) | ZA200510294B (de) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0400321A2 (hu) | 2001-06-27 | 2004-08-30 | Smithkline Beecham Corp. | Fluorpirrolidin-származékok mint dipeptidil-dipeptidáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7550590B2 (en) | 2003-03-25 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1625122A1 (de) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidylpeptidase-hemmer |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| ZA200602051B (en) | 2003-08-13 | 2007-10-31 | Takeda Pharmaceutical | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| EP1699777B1 (de) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidylpeptidase-hemmer |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| BRPI0418639B8 (pt) | 2004-03-15 | 2021-05-25 | Takeda Pharmaceutical | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| MX2007006239A (es) * | 2004-11-30 | 2007-07-20 | Hoffmann La Roche | Benzoquinolisinas sustituidas como inhibidores de dipeptidil peptidasa iv (dpp-iv) para tratamiento de diabetes. |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1917001A2 (de) * | 2005-08-11 | 2008-05-07 | F.Hoffmann-La Roche Ag | Pharmazeutische zusammensetzung mit einem dpp-iv-hemmer |
| ZA200802857B (en) | 2005-09-14 | 2009-09-30 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7833730B2 (en) | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EA200802054A1 (ru) | 2006-04-12 | 2009-04-28 | Пробиодруг Аг | Ингибиторы фермента |
| NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| CA2662419A1 (en) * | 2006-09-15 | 2008-03-20 | Stefan Abrecht | Process for the preparation of pyrido[2,1-a]isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine |
| CA2662413C (en) * | 2006-09-15 | 2015-08-25 | Stefan Abrecht | Process for the preparation of pyrido[2,1-a]isoquinoline derivatives comprising optical resolution of an enamine |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (de) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| AU2009290911A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| MX2011006713A (es) | 2008-12-23 | 2011-07-13 | Boehringer Ingelheim Int | Formas salinas de compuesto organico. |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| NZ598685A (en) | 2009-09-11 | 2013-05-31 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| CN102725291B (zh) * | 2009-10-29 | 2016-12-21 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的双环吡啶和相关的类似物 |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2560953B1 (de) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Hemmer der glutaminylzyklase |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849755A1 (de) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms |
| EP2849754B1 (de) | 2012-05-14 | 2022-09-14 | Boehringer Ingelheim International GmbH | Linagliptin, ein xanthinderivat als dpp-4-hemmer, zur verwendung bei der behandlung von sirs und/oder sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| CN104478777B (zh) * | 2015-01-13 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含硝基金刚烷和酰胺结构的衍生物、其制备方法和用途 |
| EP3253752B1 (de) * | 2015-02-06 | 2023-08-16 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isochinolin-2-yl]methanol und verbindungen, zusammensetzungen und verfahren im zusammenhang damit |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| EP3461819B1 (de) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Hemmer der glutaminylcyclase |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8302499D0 (en) * | 1983-01-29 | 1983-03-02 | Wyeth John & Brother Ltd | Benzoquinolizines |
| US5681956A (en) | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| IT1256880B (it) | 1991-07-17 | 1995-12-27 | Syntex Inc | Derivati di decaidro-8h-isochino/2,1-g/1,6/naftiridina e decaidrobenzo/a/pirrolo/2,3-e/chinolizina |
| GB9313913D0 (en) | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
| US5455351A (en) | 1993-12-13 | 1995-10-03 | Abbott Laboratories | Retroviral protease inhibiting piperazine compounds |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| IL124914A (en) * | 1997-06-26 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds |
| EP1052994A2 (de) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Verwendung von dipetidylpeptidasehemmer zur regulierung des glukosemetabolismus |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| WO2001019805A1 (en) | 1999-09-10 | 2001-03-22 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds and process for the preparation thereof |
| CA2390231A1 (en) | 1999-11-12 | 2001-05-17 | Paul Jackson | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| JP2003520849A (ja) | 2000-01-24 | 2003-07-08 | ノボ ノルディスク アクティーゼルスカブ | 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン |
| WO2001062266A2 (en) | 2000-02-25 | 2001-08-30 | Novo Nordisk A/S | Use of dpp-iv inhibitors for the treatment of diabetes |
| DK1325910T3 (da) | 2000-10-06 | 2008-11-10 | Mitsubishi Tanabe Pharma Corp | Aliphatiske nitrogenholdige femleddede ringforbindelser |
| US6727261B2 (en) * | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| WO2005000848A1 (en) | 2003-06-20 | 2005-01-06 | F. Hoffmann-La Roche Ag | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors |
-
2004
- 2004-06-11 BR BRPI0411509-0A patent/BRPI0411509A/pt not_active IP Right Cessation
- 2004-06-11 AU AU2004251829A patent/AU2004251829B2/en not_active Ceased
- 2004-06-11 ES ES04739825T patent/ES2327740T3/es not_active Expired - Lifetime
- 2004-06-11 RU RU2006101457/04A patent/RU2339636C2/ru not_active IP Right Cessation
- 2004-06-11 EP EP04739825A patent/EP1638968B1/de not_active Expired - Lifetime
- 2004-06-11 MX MXPA05013734A patent/MXPA05013734A/es active IP Right Grant
- 2004-06-11 NZ NZ543863A patent/NZ543863A/en unknown
- 2004-06-11 AT AT04739825T patent/ATE437876T1/de active
- 2004-06-11 CN CN2004800173556A patent/CN101090901B/zh not_active Expired - Fee Related
- 2004-06-11 DE DE602004022294T patent/DE602004022294D1/de not_active Expired - Lifetime
- 2004-06-11 WO PCT/EP2004/006336 patent/WO2005000846A1/en not_active Ceased
- 2004-06-11 JP JP2006515909A patent/JP4445504B2/ja not_active Expired - Fee Related
- 2004-06-11 KR KR1020057024368A patent/KR100744893B1/ko not_active Expired - Fee Related
- 2004-06-11 CA CA2528784A patent/CA2528784C/en not_active Expired - Fee Related
- 2004-06-16 TW TW093117359A patent/TW200504063A/zh unknown
- 2004-06-17 AR ARP040102106A patent/AR044796A1/es unknown
- 2004-06-17 US US10/870,268 patent/US7718666B2/en not_active Expired - Fee Related
-
2005
- 2005-12-01 NO NO20055680A patent/NO20055680L/no not_active Application Discontinuation
- 2005-12-01 IL IL172330A patent/IL172330A/en not_active IP Right Cessation
- 2005-12-15 CO CO05126707A patent/CO5640136A2/es not_active Application Discontinuation
- 2005-12-19 ZA ZA200510294A patent/ZA200510294B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005000846A1 (en) | 2005-01-06 |
| US20040259902A1 (en) | 2004-12-23 |
| NZ543863A (en) | 2009-05-31 |
| ZA200510294B (en) | 2006-12-27 |
| NO20055680D0 (no) | 2005-12-01 |
| CO5640136A2 (es) | 2006-05-31 |
| RU2339636C2 (ru) | 2008-11-27 |
| US7718666B2 (en) | 2010-05-18 |
| AU2004251829B2 (en) | 2009-12-17 |
| RU2006101457A (ru) | 2007-07-27 |
| MXPA05013734A (es) | 2006-03-08 |
| BRPI0411509A (pt) | 2006-07-25 |
| DE602004022294D1 (en) | 2009-09-10 |
| CN101090901A (zh) | 2007-12-19 |
| JP2007526876A (ja) | 2007-09-20 |
| CA2528784A1 (en) | 2005-01-06 |
| AU2004251829A1 (en) | 2005-01-06 |
| EP1638968A1 (de) | 2006-03-29 |
| EP1638968B1 (de) | 2009-07-29 |
| KR20060026431A (ko) | 2006-03-23 |
| KR100744893B1 (ko) | 2007-08-01 |
| IL172330A (en) | 2011-02-28 |
| JP4445504B2 (ja) | 2010-04-07 |
| NO20055680L (no) | 2006-01-11 |
| CA2528784C (en) | 2012-02-21 |
| CN101090901B (zh) | 2010-12-15 |
| AR044796A1 (es) | 2005-10-05 |
| TW200504063A (en) | 2005-02-01 |
| ES2327740T3 (es) | 2009-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE437876T1 (de) | Hexahydropyridoisochinoline als dpp-iv- inhibitoren | |
| ATE443054T1 (de) | Cyano-pyrrolidine als dpp-iv inhibitoren | |
| ATE489387T1 (de) | Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren | |
| ATE478868T1 (de) | Pyrrolodihydroisochinoline als pde10- inhibitoren | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| DE50304983D1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
| ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
| ATE525377T1 (de) | Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
| ATE529421T1 (de) | Chinolinderivate als phosphodiesterase-hemmer | |
| DE60304911D1 (de) | Xanthin-Derivate als DPP-IV-Inhibitoren | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
| ATE443706T1 (de) | Pyrrolotriazinverbindungen als kinaseinhibitoren | |
| NO20054852D0 (no) | GFAT inhibitorer | |
| DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
| EP1737811A4 (de) | Cetp-inhibitoren | |
| DE60320933D1 (de) | Rho-kinase inhibitoren | |
| ATE401328T1 (de) | Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren | |
| ATE529428T1 (de) | Thioxanthinderivate als myeloperoxidaseinhibitoren | |
| DE60324208D1 (de) | Biarylsulfonamide als mmp-inhibitoren | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| DE502004006055D1 (de) | 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren | |
| DE602004004295D1 (de) | 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1638968 Country of ref document: EP |
|
| UEP | Publication of translation of european patent specification |
Ref document number: 1638968 Country of ref document: EP |